Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial-Reference-Cited by-同舟云学术

Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial

Published:2015-02 Issue:2 Volume:16 Page:177-186
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Thomas Anish,Rajan Arun,Berman Arlene,Tomita Yusuke,Brzezniak Christina,Lee Min-Jung,Lee Sunmin,Ling Alexander,Spittler Aaron J,Carter Corey A,Guha Udayan,Wang Yisong,Szabo Eva,Meltzer Paul,Steinberg Seth M,Trepel Jane B,Loehrer Patrick J,Giaccone Giuseppe

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies;Engels;Int J Cancer,2003

2. Tumors of the thymus;Kuo,2004

3. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery;Margaritora;Ann Thorac Surg,2010

4. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial;Loehrer;J Clin Oncol,1994

5. Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy;Okuma;J Cancer Res Clin Oncol,2014

Cited by 232 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Analysis of Comprehensive Genomic Profile in Thymomas and Recurrent Thymomas Reveals Potentially Actionable Mutations for Target Therapies;International Journal of Molecular Sciences;2024-09-03

2. Thymic epithelial tumor medical treatment: A narrative review;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

3. Lenvatinib in combination with pembrolizumab in heavily pretreated metastatic thymic carcinoma: A case report;Current Problems in Cancer: Case Reports;2024-09

4. Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

5. Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671);Annals of Oncology;2024-09